论文部分内容阅读
高血糖是2型糖尿病相关发病与过早死亡的重要因素。目前有多类降糖药物,每类药物都具有不同的作用机制,但临床应用需全面考虑疾病的发病机制、患者的生活方式与个人背景、治疗费用等因素。最近有美国糖尿病协会(ADA)与欧洲糖尿病研究学会(EASD)联合发布的声明特别强调了这些问题,并对以患者为中心的治疗策略给出了指南。血糖控制目标的确定是灵活的,但早期干预以及根据患者个人情况尽可能严格的控制血糖是推荐的。
Hyperglycemia is an important factor in the onset and premature death of type 2 diabetes. There are many types of hypoglycemic drugs, each of which has a different mechanism of action, but the clinical application of the disease to be fully considered the pathogenesis, the patient’s lifestyle and personal background, treatment costs and other factors. Recent statements by the American Diabetes Association (ADA) in co-operation with the European Association for the Study of Diabetes (EASD) highlight these issues and give guidance on patient-centered treatment strategies. The goal of glycemic control is flexible, but early intervention and the strictest control of blood glucose based on individual patient status are recommended.